Bamboo Therapeutics

About:

Bamboo Therapeutics Announces the Acquisition of the Vector Core Manufacturing Facility from UNC-Chapel Hill

Website: http://bambootherapeutics.com/

Twitter/X: pfizer_news

Description:

Bamboo was formed to advance the work of Dr. Richard Jude Samulski, the Director of the Gene Therapy Center at the University of North Carolina (UNC), from the laboratory into human clinical trials where it could meet the requirements for drug approval. Dr. Samulski is a pioneer in the field of gene therapy. Over thirty (30) years ago, Dr. Samulski was the first person to realize the potential to use the adeno-associated virus (AAV) as a vehicle to replace a defective gene with a healthy gene. Since that time, he has re-engineered the naturally occurring virus to target delivery to certain tissues, de-target other tissues, and improve its safety. This has resulted in over twenty (20) patents related to the use of AAV for therapeutic uses. Dr. Samulski continues to lead innovation in the field of vector optimization and AAV re-engineering.

Total Funding Amount:

$49.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Chapel Hill, North Carolina, United States

Founded Date:

2014-01-01

Contact Email:

jobs(AT)bambootherapeutics.com

Founders:

Josh Grieger, Jude Samuski, Paola Leone, Sheila Ann Mikhail, Xiao Xiao

Number of Employees:

11-50

Last Funding Date:

2016-02-11

IPO Status:

Private

Industries:

© 2025 bioDAO.ai